Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.

There could be a new use for semaglutide, the main ingredient of weight loss and diabetes drugs Wegovy and Ozempic. Dr. Jon LaPook explains a study sponsored by the drugmaker found it could treat a common liver disease by reducing inflammation and scarring.